UroGen Pharma (NASDAQ:URGN) Issues Quarterly Earnings Results

UroGen Pharma (NASDAQ:URGN) issued its earnings results on Wednesday. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29, RTT News reports. The business had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same period last year, the company posted ($0.68) earnings per share.

UroGen Pharma Price Performance

NASDAQ:URGN traded down $0.14 during trading hours on Thursday, reaching $12.10. 303,960 shares of the company traded hands, compared to its average volume of 502,973. UroGen Pharma has a 1-year low of $10.60 and a 1-year high of $20.70. The stock has a market cap of $283.75 million, a P/E ratio of -3.70 and a beta of 1.12. The firm’s 50-day moving average is $12.82 and its 200-day moving average is $14.20. The company has a debt-to-equity ratio of 3.23, a current ratio of 8.15 and a quick ratio of 7.93.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on URGN shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. Guggenheim began coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 target price on the stock. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, UroGen Pharma presently has an average rating of “Buy” and a consensus price target of $48.38.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.